Work

in the two low-dose groups in the Protégé teplizumab study) proved ineff ective.

Year: 2011

Type: article

Author: Jean‐François Bach

Language: English

Topic: Diabetes and associated disorders

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2184900890

FWCI:

Cites: 21

Cited by:

Related to: 10